Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche.Methods: We retrospectively reviewed medical records of 39 females with CPP who reached menarche after GnRHa treatment (leuprolide or histrelin). CPP diagnostic criteria were breast development at <8 years old, measurable pubertal luteinizing hormone and/or estradiol concentrations, and bone age advancement. Indications to treat were advanced bone age and psychosocial concerns. Descriptive summaries were reported as frequency and proportion for categorical variables and mean and standard deviation for continuous measures. Linear regression models were developed to evaluate the associations of clinical factors with the time interval to menarche.Results: Mean age was 9.4±1.6 years at treatment onset, and treatment duration was 2.2±1.4 years. Menarche occurred at 12.6±1.1 years, which was 1.04±0.5 years after treatment discontinuation. This was negatively associated with Tanner stage of breast development and bone age at treatment onset and change in bone age during treatment. No association was seen between time interval to menarche and treatment duration, medication, or body mass index.Conclusion: We found the average time interval to menarche after GnRHa treatment in our population of female patients with CPP to be 1.04±0.5 years; this is in agreement with other reports. Tanner stage of breast development, bone age at treatment onset, and change in bone age were negatively associated with time interval to menarche. These data provide clinical correlates that assist providers during anticipatory guidance of patients with CPP after GnRHa treatment.
Abstract
Purpose: This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche.Methods: We retrospectively reviewed medical records of 39 females with CPP who reached menarche after GnRHa treatment (leuprolide or histrelin). CPP diagnostic criteria were breast development at <8 years old, measurable pubertal luteinizing hormone and/or estradiol concentrations, and bone age advancement. Indications to treat were advanced bone age and psychosocial concerns. Descriptive summaries were reported as frequency and proportion for categorical variables and mean and standard deviation for continuous measures. Linear regression models were developed to evaluate the associations of clinical factors with the time interval to menarche.Results: Mean age was 9.4±1.6 years at treatment onset, and treatment duration was 2.2±1.4 years. Menarche occurred at 12.6±1.1 years, which was 1.04±0.5 years after treatment discontinuation. This was negatively associated with Tanner stage of breast development and bone age at treatment onset and change in bone age during treatment. No association was seen between time interval to menarche and treatment duration, medication, or body mass index.Conclusion: We found the average time interval to menarche after GnRHa treatment in our population of female patients with CPP to be 1.04±0.5 years; this is in agreement with other reports. Tanner stage of breast development, bone age at treatment onset, and change in bone age were negatively associated with time interval to menarche. These data provide clinical correlates that assist providers during anticipatory guidance of patients with CPP after GnRHa treatment.
참고문헌 (28)
- Rosenfield RL, "Pediatric endocrinology", pp.2014, Elsevier
- Lee PA, "Central precocious puberty. An overview of diagnosis, treatment, and outcome", Endocrinol Metab Clin North Am, 28, pp.901~918 (1999)
- Carel JC, "Precocious puberty and statural growth", Hum Reprod Update, 10, pp.135~147 (2004)
- Brito VN, "Central precocious puberty : revisiting the diagnosis and therapeutic management", Arch Endocrinol Metab, 60, pp.163~172 (2016)
- Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~e762 (2009)
- 백준우, "Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty", Annals of Pediatric Endocrinology & Metabolism, 19(1), pp.27~31 (2014), 대한소아내분비학회
- Gillis D, "Time to menarche and final height after histrelin implant treatment for central precocious puberty", J Pediatr, 163, pp.532~536 (2013)
- Neely EK, "Leuprolide acetate 1-month depot for central precocious puberty : hormonal suppression and recovery", Int J Pediatr Endocrinol, 2010, pp.398639~ (2010)
- Tanaka T, "Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate : evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty", J Clin Endocrinol Metab, 90, pp.1371~1376 (2005)
- Paterson WF, "Auxological outcome and time to menarche following longacting goserelin therapy in girls with central precocious or early puberty", Clin Endocrinol(Oxf), 61, pp.626~634 (2004)
- Fuqua JS, "Treatment and outcomes of precocious puberty : an update", J Clin Endocrinol Metab, 98, pp.2198~2207 (2013)
- Kuczmarski RJ, "2000 CDC Growth Charts for the United States : methods and development", Vital Health Stat 11, (246), pp.1~190 (2002)
- Greulich W, "Radiographic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Bayley N, "Tables for predicting adult height from skeletal age : revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
- Heger S, "Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty : final height, body proportions, body composition, bone mineral density, and reproductive function", J Clin Endocrinol Metab, 84, pp.4583~4590 (1999)
- Lee HS, "Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty", PLoS One, 13, pp.e0201906~ (2018)
- Arrigo T, "Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment", Eur J Pediatr, 166, pp.73~74 (2007)
- Mrug S, "Early puberty, negative peer influence, and problem behaviors in adolescent girls", Pediatrics, 133, pp.7~14 (2014)
- Schoelwer MJ, "Psychological assessment of mothers and their daughters at the time of diagnosis of precocious puberty", Int J Pediatr Endocrinol, 2015, pp.5~ (2015)
- Menk TAS, "Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment : a pilot study", J Pediatr Endocrinol Metab, 30, pp.657~662 (2017)
- Mercader-Yus E, "Anxiety, self-esteem and body image in girls with precocious puberty", Rev Colomb Psiquiatr, 47, pp.229~236 (2018)
- Bereket A, "A critical appraisal of the effect of gonadotropinreleasing hormon analog treatment on adult height of girls with central precocious puberty", J Clin Res Pediatr Endocrinol, 9, pp.33~48 (2017)
- Lazar L, "Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity", J Clin Endocrinol Metab, 92, pp.3483~3489 (2007)
- Klein KO, "Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate", J Pediatr Endocrinol Metab, 31, pp.655~663 (2018)
- Micillo M, "Near final height after GnRH agonist treatment in central precocious puberty", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.787~790 (2000)
- Pasquino AM, "Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs : impact on adult height, body mass index, bone mineral content, and reproductive function", J Clin Endocrinol Metab, 93, pp.190~195 (2008)
- 정모경, "Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone", Annals of Pediatric Endocrinology & Metabolism, 19(4), pp.214~219 (2014), 대한소아내분비학회
- Korkmaz O, "The gonadotropin-releasing hormone analogue therapy may not impact final height in precocious puberty of girls with onset of puberty aged 6-8 years", J Clin Med Res, 11, pp.133~136 (2019)